Speaker Profile

M.D.,Ph.D., Dermatopathologist, Memorial Sloan Kettering Cancer Center

Biography
Dr. Hollmann is a pathologist with clinical training in dermatopathology who focuses on cutaneous tumor immunology. As a Melanoma Research Alliance young investigator and a member of both the melanoma and lung immunotherapy Stand Up to Cancer science teams, he has recently contributed to studies of the correlation between tumor neoantigens and response to immunotherapeutics. He has been involved in numerous basic and clinical investigational studies of melanoma biology and immunology. He also serves as a study pathologist for checkpoint inhibitor trials at MSK.


 Session Abstract – PMWC Silicon Valley


The development of effective anti-cancer therapies has been challenged by the overall complexity of tumors. The tumor heterogeneity is exacerbated during the progression of the cancer along with the tumor microenvironment (TME), comprised of many different cell populations, such as cancer-associated fibroblasts and various infiltrating immune cells, and non-cell components of extracellular matrix. These crucial parts of the surrounding stroma can function as both positive and negative regulators of all hallmarks of cancer development. Understanding the major events occurring in the TME that support primary tumor growth and how these events impact the modulation of the environment is of utmost relevance to assist the definition of efficient therapy strategies.